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trial Fibrillation
r Sinus Rhythm?
ontroversy and Contradiction
n Quality of Life Outcomes*
odney H. Falk, MD, FACC
oston, Massachusetts
Attempts to improve quality of life by restoring sinus rhythm
will usually be unsuccessful.
—The AFFIRM Trial Investigators (1)
Restoration and maintenance of sinus rhythm was associated
with significant increases in a number of quality of life
measurements.
—The SAFE-T Study Investigators (2)
ssessment of disease impact on quality of life can be
easured by a number of scales, of which the most
ommonly used in cardiology is probably the generic health
urvey Short Form-36 (3). There have been several studies
n which the effect of atrial fibrillation (AF) on quality of life
as been measured, and patients with this arrhythmia,
hether paroxysmal or persistent, are consistently found to
ave significant impairment on a number of aspects of
hysical and mental functioning (4). The impaired quality
f life in AF is similar in magnitude to that found in
atients who have had a myocardial infarction (5), and
uality of life measures correlate poorly with the severity of
nderlying disease (6). This suggests that it is the arrhyth-
ia rather than the associated pathology that causes the
ulk of impairment. Rather surprisingly, even “asymptom-
tic” patients with AF have been found to have an impaired
uality of life (7); perhaps this is related to the knowledge
hat they have a cardiac illness.
See page 721
Any therapy that improves quality of life must do so by
mproving some aspect of patient well-being. The SAFE-T
Sotalol Amiodarone Atrial Fibrillation Efficacy Trial) sub-
tudy reported in this issue of the Journal (2), demonstrated
modest improvement in treadmill exercise tolerance if
inus rhythm could be restored, a finding that confirms
revious data from a number of smaller studies (8–12) and
hich was also noticed, to a modest degree, in the AFFIRM
Atrial Fibrillation Follow-Up Investigation of Rhythm
anagement) trial (13). The authors also report that
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.m
From the Harvard Vanguard Medical Associates and Harvard Medical School,
oston, Massachusetts.estoration of sinus rhythm in patients with persistent AF
as associated with an improvement in quality of life
ompared to those remaining in AF. This is particularly
ntriguing in light of recent studies showing that resto-
ation of sinus rhythm in AF patients has no effect on
ortality or on major physical end points, which there-
ore implies no benefit in attempted restoration of sinus
hythm if survival or complications alone is the reason for
uch therapy (14,15).
The cardiology community is no stranger to controversy
nd contradiction, and both abound in the management of
F. The SAFE-T study quality of life findings are similar
o those reported from the Canadian Trial of Atrial Fibril-
ation (CTAF) (16), a drug efficacy study similar in design
o the SAFE-T study (17). However, data from other
tudies, foremost among them the AFFIRM (14) and
ACE (Rate Control Versus Electrical Cardioversion for
ersistent Atrial Fibrillation) (15) studies, found no im-
rovement in quality of life in a group undergoing at-
empted restoration of sinus rhythm compared with patients
andomized to a strategy of heart rate control (1,18). When
linical trials come to opposing conclusions, particularly
hen such conclusions may have significant clinical impact,
careful evaluation is mandatory to determine whether
hese apparent contradictions can be reconciled and, if so,
hat is the likely lesson. This editorial will examine some of
he arguments involved, concentrating on an analysis of the
AFE-T and AFFIRM trial conclusions.
The quality of life results in both the AFFIRM and
AFE-T trials were both based on a secondary analysis and
hus their interpretation requires a degree of caution. How-
ver, both were prospectively planned and used similar (but
ot identical) well-validated quality of life instruments in a
easonable number of patients, rendering the results robust.
he answer as to which conclusion is correct may therefore
ie in differences in the trials themselves. The AFFIRM
nvestigators required a much tighter rate control strategy
han that required in the SAFE-T study, perhaps suggest-
ng that poorer rate control might account for the difference
n quality of life. However, this is an unlikely explanation,
ecause analyses of the AFFIRM trial data based on
uartiles of achieved heart rate in the AF arm showed no
ifference in any measured outcome, including quality of
ife (19).
The SAFE-T study was a drug efficacy study, comparing
miodarone and sotalol with placebo for the maintenance of
inus rhythm in patients who had persistent AF at the time
f randomization. The AFFIRM trial recruited patients
ith either paroxysmal AF or persistent AF, and 52% of the
FFIRM trial patients randomized to rate control were
ctually in sinus rhythm at the time of randomization (20).
espite this mixture of rhythms, the AFFIRM trial analysis
f quality of life was stratified by the assigned group (rate or
hythm control) regardless of the rhythm. Thus, one argu-
ent in favor of the SAFE-T study conclusions might be
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Editorial Comment August 15, 2006:731–3hat the failure of the AFFIRM trial to demonstrate
mprovement in quality of life with rhythm control reflected
he high percentage of patients analyzed under the rubric of
rhythm control” who actually had AF at the time of
valuation and vice versa. In contrast to the AFFIRM trial,
he SAFE-T study quality of life analysis stratified patients
y the actual rhythm at the time of the questionnaire, which
as administered at baseline and 1 month and 1 year into
he study. The AFFIRM trial investigators briefly mention
hat reanalysis by actual rhythm also failed to demonstrate a
enefit of sinus rhythm over AF, whereas the other major
rial comparing rate with rhythm control, the RACE study,
ound that an ability to maintain sinus rhythm was associ-
ted with an improvement in quality of life (18).
The AFFIRM and SAFE-T studies, therefore, looked at
he question of quality of life in different ways and this may be
he key to resolving the apparently contradictory conclusions,
ecause both could be correct in their own way. One might
easonably conclude that assignation to a prospective strategy
f AF management (sinus rhythm maintenance versus allow-
ng AF to persist) does not offer a group benefit in quality of
ife of one strategy over the other. However, for the individual,
f sinus rhythm can be achieved and maintained, it may offer a
etter quality of life than would exist if AF persists or returns.
ecause patient care is fundamentally about the individual and
ot the group, this resolution would seem to be an argument in
avor of attempting to restore sinus rhythm in a patient with
ewly diagnosed AF. Unfortunately, this conclusion is proba-
ly oversimplistic. The AFFIRM trial quality of life analysis
ad the strength of being performed in previously randomized
roups. In contrast, in the SAFE-T study restoration and
aintenance of sinus rhythm was attempted in all patients, and
hen comparing outcomes the investigators were really com-
aring a group of patients that was successful in maintaining
inus rhythm with one that was unsuccessful. Thus, a host of
ndetermined factors other than the rhythm may have differ-
ntiated these groups and could account for the differences in
uality of life and exercise outcomes in the SAFE-T study.
Let us, nevertheless, assume that the SAFE-T study does
rovide compelling evidence that sinus rhythm is associated
ith a better quality of life than persistent AF. Should we
ethink the primary neutral conclusions of the AFFIRM
rial and (re)adopt a more aggressive approach to pharma-
ologic maintenance of sinus rhythm? Or is there a down-
ide to this approach? One very important factor to recog-
ize, before adopting such a strategy, is the almost total
bsence of female patients in the SAFE-T study. Although
his is understandable in a Veterans Administration study,
en and women respond differently to AF. In the CTAF
tudy, 41% of the participants were women, and their
uality of life was significantly more impaired than men,
espite comparable disease severity (21). A greater impair-
ent of quality of life in women than men with AF was also
ound in the RACE trial, and this was not affected by the
ssigned treatment strategy (22). Furthermore, while the
requency of primary end points did not differ significantlyetween men and women when rate control and rhythm
ontrol strategies were analyzed together, when analyzed
eparately there was a statistically significant 3-fold higher
ncidence of end points in women in the rhythm control
roup compared with those randomized to rate control (22).
his was driven primarily by a high incidence of side effects
f antiarrhythmic drugs and a need for pacemaker implan-
ation, and no such differences were seen in men. Although
ntiarrhythmic drug-induced bradycardia was the common-
st side effect, torsades de pointes is commoner in women,
nd this is another reason for exercising caution if consid-
ring whether sinus rhythm should be restored in an
ttempt to improve quality of life.
Data from centers with an extensive experience in
atheter-based therapies for AF suggest that nonpharmaco-
ogic therapy by ablation of fibrillation to maintain sinus
hythm results in significant improvement in quality of life
23,24). However, these techniques are still relatively new
nd highly operator dependent, and cardioversion with
ntiarrhythmic drug use remains, for now, the most com-
on approach to restoration of sinus rhythm. Given this,
hould the results of the present SAFE-T study analysis
ause the clinician to alter his or her approach to treating a
atient with newly diagnosed AF? The answer can best be
hrased in the words of the SAFE-T investigators in an
arlier publication: “The quality of life data. . .tell us less
bout the advisability of the initial treatment strategies than
bout the functional consequences of the outcomes” (17).
his is indeed true, but the results of the present analysis
hould reinforce the importance of incorporating knowledge
rom clinical trials into clinical practice while, at the same
ime, remembering that every patient, just like every trial, is
ifferent. And every patient (just like almost every trial) is
orthy of careful thought before hasty conclusions are
rawn about the value or futility of a particular management
trategy.
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